Loading
JPXHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
¥5,674
+¥17.00 · +0.30%
Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreements, research partnerships, and strategic alliances with a diverse array of organizations, including academic institutions like the University of Texas MD Anderson Cancer Center and biotech firms such as Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals Inc. Established in 1781, the company maintains its headquarters in Tokyo, Japan.
Latest quote
¥5,674
+¥17.00 · +0.30%
Regular session · JST · Market data may be delayed.
Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreements, research partnerships, and strategic alliances with a diverse array of organizations, including academic institutions like the University of Texas MD Anderson Cancer Center and biotech firms such as Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals Inc. Established in 1781, the company maintains its headquarters in Tokyo, Japan.
Day range
Current ¥5,674
52-week range
Current ¥5,674
Regular session · JST · Market data may be delayed.
Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreements, research partnerships, and strategic alliances with a diverse array of organizations, including academic institutions like the University of Texas MD Anderson Cancer Center and biotech firms such as Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals Inc. Established in 1781, the company maintains its headquarters in Tokyo, Japan.
Day range
Current ¥5,674
52-week range
Current ¥5,674
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 4.51T JPY | 4.58T JPY | 4.26T JPY | 4.03T JPY | 3.57T JPY |
| Cost of goods sold | 2.21T JPY | 2.13T JPY | 1.94T JPY | 1.73T JPY | 1.53T JPY |
| Gross profit | 2.3T JPY | 2.46T JPY | 2.32T JPY | 2.3T JPY | 2.04T JPY |
| Research and development | 675.92B JPY | 730.23B JPY | 728.62B JPY | 633.33B JPY | 526.09B JPY |
| Selling, general, and administrative | 1.08T JPY | 1.1T JPY | 1.05T JPY | 997.23B JPY | 886.33B JPY |
| Operating expenses | 1.76T JPY | 1.83T JPY | 1.79T JPY | 1.64T JPY | 1.43T JPY |
| Interest income | 211.18B JPY | 19.64B JPY | 11.29B JPY | 5.51B JPY | 4.59B JPY |
| Interest expense | 357.57B JPY | 186.98B JPY | 153.63B JPY | 136.39B JPY | 141.73B JPY |
| Depreciation and amortization | 721.13B JPY | 761.4B JPY | 728B JPY | 664.4B JPY | 583.15B JPY |
| Operating income | 540.45B JPY | 627.54B JPY | 531.42B JPY | 658.29B JPY | 610.5B JPY |
| Net income | 191.76B JPY | 107.93B JPY | 144.07B JPY | 317.02B JPY | 230.06B JPY |
Company facts updated Sep 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core TOPIX ETF1475.T26.02B0.89%2.92T JPY0.05%¥413.4-0.51%
iShares Core Nikkei 225 ETF1329.T6.04B0.29%2.08T JPY0.05%¥6,619-1.96%
Vanguard Total International Stock ETFVXUS800.56M0.12%646.2B USD0.05%$86.28-1.29%
Vanguard FTSE Developed Markets ETFVEA532.98M0.17%315B USD0.03%$71.92-1.24%
iShares Core MSCI EAFE ETFIEFA435.67M0.22%193.07B USD0.07%$98.51-0.92%
iShares MSCI Japan ETFEWJ256.39M1.08%23.22B USD0.49%$96.44-0.58%
iShares MSCI EAFE ETFEFA209.2M0.26%78.04B USD0.32%$105.66-0.84%
JPMorgan BetaBuilders Japan ETFBBJP196.81M1.00%19.62B USD0.19%$77.79-0.59%iShares Core TOPIX ETF1475.TiShares Core Nikkei 225 ETF1329.TVanguard Total International Stock ETFVXUSVanguard FTSE Developed Markets ETFVEAiShares Core MSCI EAFE ETFIEFAiShares MSCI Japan ETFEWJiShares MSCI EAFE ETFEFAJPMorgan BetaBuilders Japan ETFBBJPAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
